MedTrace Logo

COVID-19 Vaccine Reactogenicity and Immunogenicity

NCT05258708 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 179

Last updated 2022-02-28

No results posted yet for this study

Summary

Analysis of antibody kinetics after vaccination with mRNA-1273 and factors influencing the vaccine immunogenicity

Conditions

  • COVID-19
  • Vaccine Immune Response
  • Vaccine Adverse Reaction

Interventions

BIOLOGICAL

mRNA-1273 COVID-19 vaccine

two doses of mRNA-1273 vaccine at 28-day intervals

Sponsors & Collaborators

  • Catholic Kwandong University

    collaborator OTHER

  • Ajou University School of Medicine

    collaborator OTHER

  • Hallym University Kangnam Sacred Heart Hospital

    collaborator OTHER

  • Korea University Anam Hospital

    collaborator OTHER

  • Korean Center for Disease Control and Prevention

    collaborator OTHER_GOV

  • Korea University Guro Hospital

    lead OTHER

Principal Investigators

  • Joon Young Song · Korea University Guro Hospital

Eligibility

Min Age
19 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2021-06-24
Primary Completion
2022-05-30
Completion
2022-05-30
FDA Drug
Yes

Countries

  • South Korea

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05258708 on ClinicalTrials.gov